 |
110 Diseases |  |
158 Trials |
|
158 Trials |  |
1691 News |  |
| «12...678910111213141516...2728» |
- ||| amcenestrant (SAR439859) / Sanofi
Trial completion date, Metastases: AMEERA-5: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (clinicaltrials.gov) - Jun 22, 2021
P3, N=1066, Recruiting, Sponsor: Sanofi
Trial completion date: Aug 2027 --> May 2027
- goserelin acetate / Generic mfg., letrozole / Generic mfg.
[VIRTUAL] Intracardiac extension of low-grade endometrial stromal sarcoma: A case report and review of the literature () - Jun 19, 2021 - Abstract #BGCS2021BGCS_193;
MRI 18-months previous showed a multiple fibroids which were being treated locally with zoladex...Histology confirmed low grade endometrial stromal sarcoma (ESS) and letrozole was initiated...Relapse occurs in 30-50% of patients with 3 years being the median disease free interval. Conclusion This case highlights the presentation of rare disease, accurate histological diagnosis and importance of multidisciplinary team working.
- | Erleada (apalutamide) / J&J
Trial completion date, Combination therapy, Metastases: YATAGARASU: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (clinicaltrials.gov) - Jun 18, 2021
P2, N=31, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Conclusion This case highlights the presentation of rare disease, accurate histological diagnosis and importance of multidisciplinary team working. Trial completion date: Jul 2021 --> Oct 2022
- |||| Biomarker, New P2 trial: BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov) - Jun 18, 2021
P2, N=200, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | prednisone / Generic mfg., mitoxantrone / Generic mfg.
Trial completion: SWOG S9921: S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer (clinicaltrials.gov) - Jun 14, 2021
P3, N=983, Completed, Sponsor: Southwest Oncology Group
Trial completion date: Jul 2021 --> Oct 2022 Active, not recruiting --> Completed
- ||| Ibrance (palbociclib) / Pfizer
Trial completion date, Metastases: PALOMA3: Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) (clinicaltrials.gov) - Jun 2, 2021
P3, N=521, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial completion date: May 2021 --> Feb 2022
- || goserelin acetate implant / Generic mfg.
Clinical, Journal: Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China. (Pubmed Central) - May 29, 2021
P=N/A
The authors have no disclosures. NCT02430103.
- |||| goserelin acetate implant / Generic mfg., zoledronic acid / Generic mfg., capecitabine / Generic mfg.
Clinical: The oncologist, patient, and I once had a "Who's on First" conversation as the three of us discussed Zoladex, Xeloda, and Zoledronic acid and had to keep stopping and correcting ourselves (Twitter) - May 25, 2021
- dacarbazine / Generic mfg.
[VIRTUAL] MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITUTION REDUCES TOXICITY WHILE MAINTAINING EFFICACY FOR THE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA () - May 22, 2021 - Abstract #ICML2021ICML_406;
Accepting the limitations of a retrospective study, we suggest that substituting dacarbazine for procarbazine is unlikely to compromise the efficacy of eBPP and may have some toxicity benefits. Despite a predominance of high risk advanced stage patients, with nearly 2 years median follow up we have observed only 2 deaths and 4 progression events from 147 patients treated with eBPDac, suggesting this regimen is highly efficacious in Hodgkin lymphoma.
- | goserelin acetate / Generic mfg.
Biomarker, New trial, Metastases: Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - May 19, 2021
P=N/A, N=38, Not yet recruiting, Sponsor: National Taiwan University Hospital
- || giredestrant (GDC-9545) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: GO39932: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (clinicaltrials.gov) - May 19, 2021
P1a/1b, N=181, Active, not recruiting, Sponsor: Genentech, Inc.
Despite a predominance of high risk advanced stage patients, with nearly 2 years median follow up we have observed only 2 deaths and 4 progression events from 147 patients treated with eBPDac, suggesting this regimen is highly efficacious in Hodgkin lymphoma. Trial completion date: Jul 2022 --> Sep 2022 | Trial primary completion date: Jul 2022 --> Sep 2022
- || Erleada (apalutamide) / J&J
Enrollment closed, Trial completion date, Trial primary completion date: Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer (clinicaltrials.gov) - May 17, 2021
P2, N=64, Active, not recruiting, Sponsor: Instituto do Cancer do Estado de S
Trial completion date: Jul 2022 --> Sep 2022 | Trial primary completion date: Jul 2022 --> Sep 2022 Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Mar 2021 --> Sep 2021
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: STAMP: Strength, Aging, and Memory in Prostate Cancer (clinicaltrials.gov) - May 15, 2021
P=N/A, N=60, Not yet recruiting, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Mar 2021 --> Sep 2021 Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
- dacarbazine / Generic mfg.
[VIRTUAL] MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITUTION REDUCES TOXICITY WHILE MAINTAINING EFFICACY FOR THE TREATMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA. () - May 13, 2021 - Abstract #EHA2021EHA_556;
Conclusion Accepting the limitations of a retrospective study, we suggest that substituting dacarbazine for procarbazine is unlikely to compromise the efficacy of eBPP and may have some toxicity benefits. Despite a predominance of high risk advanced stage patients, with nearly 2 years median follow-up we have observed only 2 deaths and 4 progression events from 147 patients treated with eBPDac, suggesting this regimen is highly efficacious for the treatment of Hodgkin lymphoma.
- | goserelin acetate / Generic mfg.
Trial primary completion date: Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose (clinicaltrials.gov) - May 12, 2021
P=N/A, N=40, Recruiting, Sponsor: Norwegian School of Sport Sciences
Despite a predominance of high risk advanced stage patients, with nearly 2 years median follow-up we have observed only 2 deaths and 4 progression events from 147 patients treated with eBPDac, suggesting this regimen is highly efficacious for the treatment of Hodgkin lymphoma. Trial primary completion date: Apr 2019 --> Apr 2022
- || Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov) - May 11, 2021
P2, N=327, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2019 --> Apr 2022 Trial primary completion date: Mar 2021 --> Jun 2021
- || goserelin acetate / Generic mfg.
Enrollment change, Trial withdrawal, Head-to-Head: LARES: To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer. (clinicaltrials.gov) - May 9, 2021
P3, N=0, Withdrawn, Sponsor: AstraZeneca
Trial primary completion date: Mar 2021 --> Jun 2021 N=168 --> 0 | Not yet recruiting --> Withdrawn
- tamoxifen / Generic mfg.
[VIRTUAL] Trends in use of ovarian suppression (OS) for premenopausal patients with early-stage hormone positive breast cancer and Intermediate Risk (IR) Oncotype Recurrence Scores (RS) from 2006-2020: A retrospective database analysis. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3597;
This study shows how the results of the SOFT-TEXT trial have been adapted into current practice . Future studies are needed to evaluate real-world recurrence rates with the use of increased OS and whether chemotherapy rates have decreased over time.
- amcenestrant (SAR439859) / Sanofi, Ibrance (palbociclib) / Pfizer
[VIRTUAL] AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1399;
P3
Fulvestrant is currently the only SERD available for advanced BC but requires intramuscular administration, limiting the applied dose, exposure and receptor engagement...The study includes men, pre/peri-menopausal (with goserelin) and post-menopausal women...Biomarkers will be measured in paired tumor biopsies and cell free deoxyribonucleic acid (cfDNA) over time . Target enrolment = 1066 pts; enrolment as of 1/2021 = 33 pts.
- tamoxifen / Generic mfg., fulvestrant / Generic mfg.
[VIRTUAL] Relative risk of pneumonitis or interstitial lung disease (ILD) associated with the use of cyclin-dependent kinase inhibitors (CDK4/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1367;
Cyclin-dependent kinase 4/6 inhibitors are associated with increased risk of any grade pneumonitis or ILD . Early detection and prompt initiation of appropriate interventions are vital to reduce the morbidity and mortality associated with CDK4/6i induced pneumonitis or ILD.
- ||| Piqray (alpelisib) / Novartis
Enrollment closed, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Apr 28, 2021
P2, N=382, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Early detection and prompt initiation of appropriate interventions are vital to reduce the morbidity and mortality associated with CDK4/6i induced pneumonitis or ILD. Recruiting --> Active, not recruiting
- | Erleada (apalutamide) / J&J
Trial primary completion date, Combination therapy, Metastases: YATAGARASU: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (clinicaltrials.gov) - Apr 22, 2021
P2, N=31, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2021 --> Jun 2021
- ||| Ibrance (palbociclib) / Pfizer
Trial primary completion date: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer (clinicaltrials.gov) - Apr 22, 2021
P3, N=200, Recruiting, Sponsor: Kyoto Breast Cancer Research Network
Trial primary completion date: Mar 2021 --> Jun 2021 Trial primary completion date: Mar 2021 --> Nov 2021
- | goserelin acetate / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial primary completion date: SEAT: Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients (clinicaltrials.gov) - Apr 22, 2021
P2, N=110, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial primary completion date: Mar 2021 --> Nov 2021 Trial primary completion date: Dec 2020 --> Dec 2021
- ||| Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Apr 22, 2021
P3, N=3255, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2020 --> Dec 2021 Trial completion date: May 2021 --> May 2022
- | goserelin acetate / Generic mfg.
Trial completion date, Metastases: g-RAMPP: Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases (clinicaltrials.gov) - Apr 22, 2021
P=N/A, N=452, Active, not recruiting, Sponsor: Martini-Klinik am UKE GmbH
Trial completion date: May 2021 --> May 2022 Trial completion date: Apr 2023 --> Dec 2026
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
New trial: STAMP: Strength, Aging, and Memory in Prostate Cancer (clinicaltrials.gov) - Apr 20, 2021
P, N=60, Not yet recruiting, Sponsor: University of Nebraska
- |||| goserelin acetate / Generic mfg., bicalutamide / Generic mfg.
Enrollment open, Metastases: A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy. (clinicaltrials.gov) - Apr 8, 2021
P4, N=871, Recruiting, Sponsor: AstraZeneca
Trial completion date: Apr 2023 --> Dec 2026 Not yet recruiting --> Recruiting
- ||| Kisqali (ribociclib) / Novartis
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: AMALEE: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Apr 2, 2021
P2, N=376, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2026 --> Jun 2021
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Rubraca (rucaparib) / Pharma& Schweiz
Trial suspension, Metastases: CASPAR: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (clinicaltrials.gov) - Mar 21, 2021
P3, N=1002, Suspended, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2026 --> Jun 2021 Not yet recruiting --> Suspended
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., flutamide / Generic mfg.
Trial completion date: Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer (clinicaltrials.gov) - Mar 9, 2021
P3, N=226, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Suspended Trial completion date: Dec 2020 --> Dec 2021
- | New P2/3 trial, Metastases: VA STARPORT: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (clinicaltrials.gov) - Mar 9, 2021
P2/3, N=464, Not yet recruiting, Sponsor: VA Office of Research and Development
- | Nubeqa (darolutamide) / Bayer, Orion Corp
Enrollment open, Surgery: Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (clinicaltrials.gov) - Mar 3, 2021
P3, N=810, Recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
Trial completion date: Dec 2020 --> Dec 2021 Not yet recruiting --> Recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Trial primary completion date, Metastases: LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Mar 3, 2021
P2, N=92, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Not yet recruiting --> Recruiting Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- || giredestrant (GDC-9545) / Roche
Enrollment closed, Combination therapy, Metastases: GO39932: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (clinicaltrials.gov) - Mar 1, 2021
P1a/1b, N=181, Active, not recruiting, Sponsor: Genentech, Inc.
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Recruiting --> Active, not recruiting
- ||| amcenestrant (SAR439859) / Sanofi
Trial completion date, Metastases: AMEERA-5: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (clinicaltrials.gov) - Feb 25, 2021
P3, N=1066, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Trial completion date: Sep 2026 --> Aug 2027
- | Suprefact (buserelin acetate) / Sanofi, Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
Enrollment open: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov) - Feb 25, 2021
P3, N=2478, Recruiting, Sponsor: NRG Oncology
Trial completion date: Sep 2026 --> Aug 2027 Not yet recruiting --> Recruiting
- | Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono
Trial completion date, Trial primary completion date: ImmunoADAPT: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Feb 24, 2021
P2, N=40, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Not yet recruiting --> Recruiting Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- | Kisqali (ribociclib) / Novartis
Biomarker, Enrollment open, Trial initiation date: LEANORA: Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts (clinicaltrials.gov) - Feb 23, 2021
P=N/A, N=36, Recruiting, Sponsor: Georgetown University
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Not yet recruiting --> Recruiting | Initiation date: Dec 2020 --> Mar 2021
- ||||| Emcyt (estramustine) / Pfizer, Nippon Shinyaku
Enrollment change, Metastases: Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse (clinicaltrials.gov) - Feb 23, 2021
P3, N=413, Active, not recruiting, Sponsor: UNICANCER
Not yet recruiting --> Recruiting | Initiation date: Dec 2020 --> Mar 2021 N=250 --> 413
- | docetaxel / Generic mfg.
Trial completion, Metastases: Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Feb 21, 2021
P3, N=385, Completed, Sponsor: UNICANCER
N=250 --> 413 Active, not recruiting --> Completed
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Erleada (apalutamide) / J&J
Enrollment closed, Trial completion date, Trial primary completion date: Micro RNAs to Predict Response to Androgen Deprivation Therapy (clinicaltrials.gov) - Feb 21, 2021
P=N/A, N=60, Active, not recruiting, Sponsor: Medical College of Wisconsin
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Feb 2022 --> Jun 2023 | Trial primary completion date: Feb 2021 --> Jun 2022
- ||||| amcenestrant (SAR439859) / Sanofi
Enrollment change, Trial primary completion date, Metastases: AMEERA-5: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (clinicaltrials.gov) - Feb 21, 2021
P3, N=1066, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | Trial completion date: Feb 2022 --> Jun 2023 | Trial primary completion date: Feb 2021 --> Jun 2022 N=810 --> 1066 | Trial primary completion date: May 2024 --> Jan 2024
- | Trial completion date, Trial primary completion date: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov) - Feb 10, 2021
P2, N=50, Recruiting, Sponsor: Washington University School of Medicine
N=810 --> 1066 | Trial primary completion date: May 2024 --> Jan 2024 Trial completion date: Jun 2025 --> Jan 2028 | Trial primary completion date: Jun 2021 --> Jun 2023
- || Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Metastases: MONALEESASIA: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (clinicaltrials.gov) - Feb 4, 2021
P1, N=88, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jun 2025 --> Jan 2028 | Trial primary completion date: Jun 2021 --> Jun 2023 Trial completion date: Oct 2020 --> Feb 2022 | Trial primary completion date: Oct 2020 --> Jan 2022
- | abiraterone acetate / Generic mfg.
New P2 trial: Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate (clinicaltrials.gov) - Feb 3, 2021
P2, N=50, Not yet recruiting, Sponsor: West China Hospital
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Talzenna (talazoparib) / Pfizer
New P2 trial: Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov) - Feb 2, 2021
P2, N=70, Not yet recruiting, Sponsor: City of Hope Medical Center
- || Rozlytrek (entrectinib) / Roche
Enrollment open, Combination therapy: Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) (clinicaltrials.gov) - Jan 28, 2021
P2, N=45, Recruiting, Sponsor: Jules Bordet Institute
Trial completion date: Oct 2020 --> Feb 2022 | Trial primary completion date: Oct 2020 --> Jan 2022 Not yet recruiting --> Recruiting
- | docetaxel / Generic mfg.
Trial completion date, Metastases: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov) - Jan 27, 2021
P1, N=20, Active, not recruiting, Sponsor: Medical University of South Carolina
Not yet recruiting --> Recruiting Trial completion date: Dec 2020 --> Dec 2021
- | Kisqali (ribociclib) / Novartis
Trial completion date, Metastases: TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer (clinicaltrials.gov) - Jan 22, 2021
P1, N=7, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Dec 2020 --> Dec 2021 Trial completion date: Dec 2020 --> Jun 2021